复发/难治性多发性骨髓瘤中B细胞成熟抗原导向的嵌合抗原受体T细胞治疗后结局预测模型的开发与验证
这项国际回顾性观察研究纳入欧洲136例和美国133例接受BCMA CAR-T治疗的复发/难治性多发性骨髓瘤患者,构建MyCARe模型预测早期复发。模型以髓外病变或浆细胞白血病、来那度胺难治、高危细胞遗传学和淋巴清除时铁蛋白升高各计1分,分低危0-1分、中危2-3分和高危4分,5个月复发/进展率分别为7%、27%和53%(P<.001),并在美国队列中外部验证。
要点
- MyCARe模型基于4项独立预测因子各计1分,分低危0-1分、中危2-3分和高危4分。
- 5个月复发/进展率低危7%、中危27%、高危53%(P<.001)。
- 输注后<5个月早期复发者12个月总生存欧洲30%、美国14%。
核心结论
- 欧洲与美国复发/难治性多发性骨髓瘤患者CAR-T治疗后结局相当。
- MyCARe模型可能有助于在特定患者亚组中优化CAR-T细胞的时机选择。
研究设计与样本
- 国际回顾性观察研究,纳入接受目前可用商业或学术制备的抗B细胞成熟抗原(BCMA)CAR-T治疗的复发/难治性多发性骨髓瘤患者。
- 欧洲队列136例,美国队列133例;在欧洲训练队列构建模型,在美国队列外部验证。
主要发现
- 总缓解率为87%,两队列相当;完全缓解欧洲48%、美国49%。
- 中位至复发时间为5个月;输注后<5个月早期复发者生存差,12个月总生存欧洲30%、美国14%。
- 髓外病变或浆细胞白血病、来那度胺难治、高危细胞遗传学、淋巴清除时铁蛋白升高为早期复发/进展的独立预测因子。
- MyCARe模型与5个月复发/进展发生率显著相关(P<.001):低危7%、中危27%、高危53%。
- 模型在美国队列中得到验证,并在各亚组中保持对缓解、生存和结局的预后效用。
关键数值与推荐
- 每项独立预测因子计1分:髓外病变或浆细胞白血病、来那度胺难治、高危细胞遗传学、淋巴清除时铁蛋白升高。
- 风险分层:0-1分为低危,2-3分为中危,4分为高危。
- 5个月复发/进展率:低危7%、中危27%、高危53%(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T. PATIENTS AND METHODS: This is an international retrospective observational study including patients with RRMM infused with currently available commercial or academically produced anti-B-cell maturation antigen (BCMA) CAR-T. We describe characteristics and outcomes in Europe (n = 136) and the United States (n = 133). Independent predictors of relapse/progression built a simple prediction model (Myeloma CAR-T Relapse [MyCARe] model) in the training cohort (Europe), which was externally validated (US cohort) and tested within patient- and treatment-specific subgroups. RESULTS: The overall response rate was 87% and comparable between both cohorts, and complete responses were seen in 48% (Europe) and 49% (the United States). The median time to relapse was 5 months, and early relapse <5 months from infusion showed poor survival across cohorts, with the 12-month overall survival of 30% (Europe) and 14% (the United States). The presence of extramedullary disease or plasma cell leukemia, lenalidomide-refractoriness, high-risk cytogenetics, and increased ferritin at the time of lymphodepletion were independent predictors of early relapse or progression. Each factor received one point, forming the three-tiered MyCARe model: scores 0-1 (low risk), scores 2-3 (intermediate risk), and a score of 4 (high risk). The MyCARe model was significantly associated with distinct 5-month incidence of relapse/progression (P < .001): 7% for low-risk, 27% for intermediate-risk, and 53% for high-risk groups. The model was validated in the US cohort and maintained prognostic utility for response, survival, and outcomes across subgroups. CONCLUSION: Outcomes of patients with RRMM after CAR-T are comparable between Europe and the United States. The MyCARe model may facilitate optimal timing of CAR-T cells in patient-specific subgroups.
引用
- Gagelmann N, Dima D, Merz M, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024. PMID: 38358946. doi:10.1200/JCO.23.02232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。